Search results
Results from the WOW.Com Content Network
Anemia and thrombocytopenia may require blood transfusion. Neutropenia ... In the 1970s, antineoplastic (chemotherapy) drugs were identified as hazardous, ...
This page was last edited on 16 January 2025, at 18:41 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
Before their use in chemotherapy, alkylating agents were better known for their use as sulfur mustard, ("mustard gas") and related chemical weapons in World War I. The nitrogen mustards were the first alkylating agents used medically, as well as the first modern cancer chemotherapies. Goodman, Gilman, and others began studying nitrogen mustards ...
Sugemalimab, sold under the brand name Cejemly among others, is a monoclonal antibody used for the treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy. [1] It is an antineoplastic monoclonal antibody that potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD ...
284.9 Aplastic anemia unspecified; 285 Other and unspecified anemias. 285.0 Sideroblastic anemia; 285.1 Acute posthemorrhagic anemia; 285.2 Anemia in chronic illness. 285.21 Anemia in chronic kidney disease; 285.22 Anemia in neoplastic disease; 285.29 Anemia of other chronic illness; 285.3 Antineoplastic chemotherapy induced anemia; 285.8 Other ...
The most common side effects include alopecia (hair loss), nausea, diarrhea, anemia (reduced number of red blood cells) and asthenia (lack of energy). [5] [8] [3] It can cause worsening of chemotherapy induced neutropenia (low level of white blood cells). [5] It may cause harm to a developing fetus or a newborn baby. [5]
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Dicycloplatin is a chemotherapy medication used to treat a number of cancers which includes the non-small-cell lung carcinoma and prostate cancer. [1]Some side effects which are observed from the treatment by dicycloplatin are nausea, vomiting, thrombocytopenia, neutropenia, anemia, fatigue, loss of appetite, liver enzyme elevation and alopecia.